Is Auris Medical Holding AG (EARS)’s Fuel Running Low? The Stock Reaches 52 Week Low Today

May 28, 2018 - By Darrin Black

The stock of Auris Medical Holding AG (NASDAQ:EARS) hit a new 52-week low and has $1.15 target or 3.00 % below today’s $1.19 share price. The 6 months bearish chart indicates high risk for the $7.28M company. The 1-year low was reported on May, 28 by If the $1.15 price target is reached, the company will be worth $218,400 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 0.83% or $0.01 during the last trading session, reaching $1.19. About 283,540 shares traded. Auris Medical Holding AG (NASDAQ:EARS) has declined 80.78% since May 28, 2017 and is downtrending. It has underperformed by 92.33% the S&P500.

More notable recent Auris Medical Holding AG (NASDAQ:EARS) news were published by: which released: “Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results” on May 15, 2018, also with their article: “Auris Medical’s (EARS) CEO Thomas Meyer on Q1 2018 Results – Earnings Call Transcript” published on May 15, 2018, published: “Auris Medical up 41%” on May 04, 2018. More interesting news about Auris Medical Holding AG (NASDAQ:EARS) were released by: and their article: “Benzinga Pro’s 5 Stocks To Watch Today” published on May 07, 2018 as well as‘s news article titled: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” with publication date: May 25, 2018.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. The company has market cap of $7.28 million. The Company’s product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. It currently has negative earnings. The firm is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.